Crossmark

Effect of clinically approved HDAC inhibitors on Plasmodium, Leishmania and Schistosoma parasite growth

Crossref DOI link: https://doi.org/10.1016/j.ijpddr.2016.12.005

Published Print: 2017-04

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Chua, Ming Jang https://orcid.org/0000-0002-3891-1913
Arnold, Megan S.J.

Xu, Weijun

Lancelot, Julien

Lamotte, Suzanne https://orcid.org/0000-0003-2699-7219
Späth, Gerald F.

Prina, Eric

Pierce, Raymond J. https://orcid.org/0000-0001-9820-8608
Fairlie, David P.

Skinner-Adams, Tina S.

Andrews, Katherine T.
Funding

Funding for this research was provided by:

Centre National de la Recherche Scientifique

Université de Lille

Seventh Framework Programme (602080)

Medical Research Council

Institute Pasteur De Lille

Australian Research Council (CE140100011)

Griffith University

National Health and Medical Research Council (1027369)

National Health and Medical Research Council (APP1074016)

National Health and Medical Research Council (APP1093378)
License Information

Text and Data Mining valid from 2017-04-01

Text and Data Mining valid from 2017-04-01

Version of Record valid from 2016-10-30
More Information

This article is maintained by: Elsevier

Article Title: Effect of clinically approved HDAC inhibitors on Plasmodium, Leishmania and Schistosoma parasite growth

Journal Title: International Journal for Parasitology: Drugs and Drug Resistance

CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.ijpddr.2016.12.005

Content Type: article

Copyright: © 2017 The Authors. Published by Elsevier Ltd on behalf of Australian Society for Parasitology.